VBI Vaccines (VBIV) Announces Interim Data from Sci-B-Vac Phase IV in HBV; Strong Seroprotection Rates Noted
Tweet Send to a Friend
VBI Vaccines Inc. (Nasdaq: VBIV) reported interim results from an ongoing Phase IV postmarketing study to evaluate Sci-B-Vac, VBI's licensed ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
